logo
Share SHARE
FONT-SIZE Plus   Neg

Par Pharmaceutical To Be Taken Private By TPG In $1.9 Bln Deal

Specialty pharmaceutical company Par Pharmaceutical Companies, Inc. (PRX) agreed Monday to be taken private by an affiliate of private equity firm TPG for $50.00 per share in an all-cash deal valued at $1.9 million.

The deal, which is primarily subject to approval of a majority of Par's outstanding shares, is expected to close in 2012. The deal has the unanimous approval of Par's board.

"We are excited for the opportunity to invest in Par, a leading generic pharmaceutical company that has a long track record of success via its focus on complex products and its strong, diversified product pipeline," TPG Partner Todd Sisitsky said in a statement.

The offer price represents a 37 percent premium over the Par Pharma's closing share price of $36.58 on Friday.

Following the announcement, Par Pharma's shares are surging more than 36 percent in pre-market trading in a bid to match the offer price. The deal is not subject to a financing condition.

The deal will see TGP "benefit from the strong macro trends of a greater focus on cost effective healthcare solutions and the increasing demands from an aging population."

The terms of the deal provides for generic drug maker Par Pharma to solicit superior proposals from third parties through August 24.

TPG is a leading global private investment firm founded in 1992 with $51.5 billion of assets under management, with extensive experience with global public and private investments. The firm's major investments in the healthcare sector include Aptalis Pharma, Biomet, Immucor, and IMS Health.

"While my focus and that of the Par Board of Directors was on shareholder value, we are very pleased that Par will be acquired by TPG, a leading global private investment firm whose substantial resources and healthcare experience will enable Par to continue to invest in its future long-term growth," Par's Chairman and CEO Patrick LePore noted.

PRX closed Friday's regular trading session at $36.58, up $0.57 on a volume of 0.11 million shares, higher than the three-month average volume of 0.39 million shares. In the past 52-week period, the stock has been trading in a range of $24.85 to $42.80.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier. Department store chain J.C. Penney Co. Inc. on Friday reported a turnaround to profit in the fourth quarter as a slight decline in sales was more than offset by lower expenses. Adjusted earnings per share for the quarter beat analysts' expectations, while revenues slightly missed their estimates. Earlier today, J.C. Penny announced a plan to optimize its national retail operations. Google is planning to significantly expand a carpool service on its navigational app Waze, according to a report in the Wall Street Journal. The move indicates the company is edging closer to a potential clash with ride-hailing service Uber Technologies Inc.
comments powered by Disqus
Follow RTT